Studying how doctors make decisions together in gynecologic cancer tumor boards
Surveys doctors after tumor board meetings on ovarian and uterine cancer cases.
Key facts
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Where
- Roma, ItalySee the site
- Trial code
- Registry title
- Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology
- Status
- Not yet recruiting
- People taking part
- 400 people, planned
- Started
- 13 Jul 2026
- Expected to end
- 31 Mar 2027
- Type of study
- Observational
- Treatments tested
- Online Survey Assessment of Tumor Board Group Dynamics
- Record updated
- 12 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for physicians who take part in the full ovarian and uterine cancer tumor board meetings and help make treatment decisions. They fill in an online survey after each meeting.
- Age
- 18 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Attending only part of a tumor board session
- Trainees or other attendees not directly involved in clinical decisions
- Physicians who only consult occasionally, for less than 50% of the study period
- Incomplete survey completion
- Extra members of the same specialty or role with lower participation may be excluded
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Physicians participating in the clinical decision-making process within ovarian and uterine cancer multidisciplinary tumor board meetings
- Participation in the full tumor board session
- Participation either in person or online
- Representation of at least one relevant specialty or role involved in the clinical decision-making process
Who cannot take part
- Partial attendance at the ovarian and uterine cancer multidisciplinary tumor board session
- Trainees or other attendees not directly involved in the clinical decision-making process
- Physicians whose specialty contribution consists of occasional consultation for less than 50% of the study period
- Incomplete survey completion
- If more than one member represents the same specialty or role, participants with lower participation in the clinical decision-making process may be excluded
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia OncologicaRoma, ItalyContact: Carmine Conte, DrNo longer taking part
About the trial
What the trial wants to find out
Study Title Group Dynamics Evaluation in Gynecologic Multidisciplinary Tumor Boards - GOLD Study
Read full original descriptionShow less
Background and Rationale Multidisciplinary Tumor Boards are central to complex oncologic decision-making. In gynecologic oncology, clinical decisions often require the integration of knowledge from different specialties, including surgery, medical oncology, radiology, pathology, radiation oncology, and other relevant disciplines. These teams function not only as groups of specialists but also as collective decision-making systems, where communication, collaboration, information sharing, psychological safety, and group dynamics may influence the quality of clinical discussion and final recommendations.
Study Objective The GOLD Study aims to investigate the decision-making process and group dynamics within ovarian and uterine cancer Multidisciplinary Tumor Boards. The study will assess how communication patterns, collaboration, minority dissent, team cohesion, team learning, task interdependence, collective information processing, individual information processing, and psychological safety contribute to Tumor Board performance.
Study Design This is a single-center, prospective, longitudinal observational study involving physicians participating in ovarian and uterine cancer Multidisciplinary Tumor Boards, either in person or online.
Methods At the end of each Tumor Board meeting, participating physicians will complete an online survey using Microsoft Forms. The questionnaire was developed within a scientific collaboration with the Department of Business and Management of LUISS Guido Carli University and includes validated measurement scales derived from the literature. In addition, data on team composition and participation will be collected for each meeting.
Statistical Analysis Survey data and participation data will be analyzed using descriptive statistics, inferential methods, and social network analysis. Network measures such as density and centralization indices will be used to evaluate the structure of interactions and participation over time. Statistical analyses will be performed using Stata, R, and UCINET where appropriate.
Target Population and Sample Size The target population includes physicians involved in the clinical decision-making process during ovarian and uterine cancer Tumor Boards. A total of approximately 400 questionnaires is planned, based on the rule of thumb of at least 10 respondents per questionnaire variable.
Study Duration The expected study duration is six months.
The group in the trial
- Group/Cohort Label: Gynecologic Multidisciplinary Tumor Board Physicians
Physicians involved in clinical decision-making during ovarian and uterine cancer multidisciplinary tumor board meetings. Participants complete an online survey after each meeting; no intervention is administered.
Treatment: Online Survey Assessment of Tumor Board Group Dynamics
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Group Dynamics Evaluation in ginecOlogic muLtidisciplinary Tumor boarDs
- Plain-language title
- Studying how doctors make decisions together in gynecologic cancer tumor boardsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 12 June 2026